Vital Signs Inc.
Division of General Electric Co.
Latest From Vital Signs Inc.
Given Imaging, soon to be part of Covidien, gained clearance for PillCam Colon capsule endoscopy device. FDA approves its first continuous glucose monitoring system for kids. Congress makes progress in the sustainable growth rate formula bill. More news.
To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.
Egalet secured Shionogi as its first major partner in a deal focused on abuse-deterring forms of hydrocodone; to complement its specialty pharmacy portfolio, CVS acquired the infusion therapy business Coram for $2.1 billion. A $729 million debt offering by Incyte made up nearly one-third of the $2.5 billion in biopharma financing; and sources of public fundraising have been increasing over the past few months in the device industry, which raised $532 million.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced October-November 2013.
- Monitoring Equipment & Devices
- Therapeutic Areas
- Neurology, Nervous System
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- General Electric Co.
- Senior Management
Terence D Wall, Chmn., Pres. & CEO
Mark Mishler, EVP, CFO
John R Eason, EVP, Global Bus. Dev.
Mark Jefferson, VP, Sales & Mktg.
- Contact Info
Vital Signs Inc.
Phone: (973) 790-1330
20 Campus Rd.
Totowa, NJ 07512
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.